{"id":"W2596506481","doi":"10.1093/infdis/jix024","title":"Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON)","year":2017,"lang":"en","type":"article","venue":"The Journal of Infectious Diseases","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Gilead Sciences; Abbott Laboratories","keywords":"Medicine; HBeAg; Internal medicine; Gastroenterology; Seroconversion; Peginterferon alfa-2a; Entecavir; Combination therapy; Pegylated interferon; Hepatitis B virus; Randomized controlled trial; Adverse effect; Hepatitis B; Immunology; Lamivudine; HBsAg; Chronic hepatitis; Virus; Ribavirin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005974118,0.0005949727,0.0028985,0.0004555657,0.0006298614,0.000130352,0.000271591,0.0001173641,0.0002125131],"category_scores_gemma":[0.001874405,0.0003056212,0.0007092947,0.0001925,0.0005496487,0.0003228483,0.0000737087,0.0003661991,0.00003723982],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001694098,"about_ca_system_score_gemma":0.0005454849,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03604937,"about_ca_topic_score_gemma":0.05667533,"domain_scores_codex":[0.9961089,0.001098601,0.001338922,0.0003014533,0.0006521987,0.0004999206],"domain_scores_gemma":[0.9954954,0.001110105,0.001831721,0.0005796927,0.0006934955,0.0002895483],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5160655,0.001626082,0.4762245,0.00001611791,0.002463316,0.000355364,0.0005038094,0.00004011768,0.0000370736,0.000006602429,0.0001635422,0.002497952],"study_design_scores_gemma":[0.5506081,0.01474253,0.4313816,0.0006883288,0.001841599,0.00006038613,0.00001113224,0.0001118051,0.0002805912,0.00003212382,0.00003986148,0.0002019552],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918845,0.001206348,0.00003118785,0.0002645259,0.0004346826,0.005003881,0.0001709367,0.00004982121,0.0009541683],"genre_scores_gemma":[0.9807994,0.01810966,0.000008041505,0.0001662129,0.0003963341,0.0002649543,0.00004484347,0.00006412427,0.0001463877],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04484292,"threshold_uncertainty_score":0.9999396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009156460522759861,"score_gpt":0.2626140961784473,"score_spread":0.2534576356556874,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}